A multinational pharmaceutical company is promising 45 jobs in an €45m expansion of it Dublin operations by building a new manufacturing facility.
Construction of Mallinckrodt's facility at Blanchardstown will take two years and will provide work for 300 builders.
The company provides treatment options for patients with a wide variety of health conditions, with a focus on autoimmune and rare diseases, analgesia, neonatal critical care respiratory therapies and central nervous system disorders.
It already employs over 120 people at its existing manufacturing site and offices in Dublin.
Mark Trudeau, the CEO and President of Mallinckrodt, said the company proud to have had a significant presence in Ireland for over two decades, and today marks an important step for the company.
"Our Irish workforce has served as a tremendous asset to our global operations to date. We are particularly pleased to be making this sizeable capital investment today, continuing our long-standing operations in Ireland," he added.
